GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
Jul 24, 2017
OTC Disclosure & News Service
-
GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
ATLANTA, GA--(Marketwired - Jul 24, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with The Scripps Research Institute (TSRI) in La Jolla, CA, and the Institute of Human Virology (IHV) at the University of Maryland Medical School in Baltimore, MD, for advanced development of a preventive vaccine against Lassa hemorrhagic fever virus (LASV).
GeoVax previously announced that its LASV vaccine candidate, GEO-LM01, provided 100% protection after single immunization, to mice infected with a lethal dose of a LASV reassortant. The intent of the three-way collaboration with TSRI and IHV is to evaluate additional LASV vaccine candidates to elucidate involvement of humoral and cellular arms of immunity in protection against LASV infections.
Farshad Guirakhoo, PhD, GeoVax's Chief Scientific Officer, commented, "We are pleased to expand our collaboration with IHV, and to now work with Professor Erica Ollmann Saphire, PhD at TSRI as well, an expert in the structure of LASV and other viral hemorrhagic fever viruses. Our MVA-VLP vaccine platform is well-suited for quickly generating various candidates and testing them using a LASV reassortant challenge model developed at IHV."
"The structural studies from the Saphire lab will help broaden and strengthen humoral immune responses to LASV. Fortunately, the MVA platform can easily accommodate these new constructs," noted Maria Salvato, PhD, Professor of Medicine, Institute of Human Virology, University of Maryland School of Medicine.
"A major scientific challenge will be finding the best way to elicit a protective antibody response," said Dr. Saphire. "Combining approaches and collaborative teams are the best way forward to developing these much-needed vaccines for human health."
Jul 24, 2017
OTC Disclosure & News Service
-
GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
ATLANTA, GA--(Marketwired - Jul 24, 2017) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with The Scripps Research Institute (TSRI) in La Jolla, CA, and the Institute of Human Virology (IHV) at the University of Maryland Medical School in Baltimore, MD, for advanced development of a preventive vaccine against Lassa hemorrhagic fever virus (LASV).
GeoVax previously announced that its LASV vaccine candidate, GEO-LM01, provided 100% protection after single immunization, to mice infected with a lethal dose of a LASV reassortant. The intent of the three-way collaboration with TSRI and IHV is to evaluate additional LASV vaccine candidates to elucidate involvement of humoral and cellular arms of immunity in protection against LASV infections.
Farshad Guirakhoo, PhD, GeoVax's Chief Scientific Officer, commented, "We are pleased to expand our collaboration with IHV, and to now work with Professor Erica Ollmann Saphire, PhD at TSRI as well, an expert in the structure of LASV and other viral hemorrhagic fever viruses. Our MVA-VLP vaccine platform is well-suited for quickly generating various candidates and testing them using a LASV reassortant challenge model developed at IHV."
"The structural studies from the Saphire lab will help broaden and strengthen humoral immune responses to LASV. Fortunately, the MVA platform can easily accommodate these new constructs," noted Maria Salvato, PhD, Professor of Medicine, Institute of Human Virology, University of Maryland School of Medicine.
"A major scientific challenge will be finding the best way to elicit a protective antibody response," said Dr. Saphire. "Combining approaches and collaborative teams are the best way forward to developing these much-needed vaccines for human health."
